IntoCell (A287840) Stock Overview
Develops protein-drug conjugates for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A287840 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
IntoCell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩23,000.00 |
| 52 Week High | ₩74,900.00 |
| 52 Week Low | ₩20,200.00 |
| Beta | 0 |
| 1 Month Change | -8.91% |
| 3 Month Change | -39.63% |
| 1 Year Change | -45.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.72% |
Recent News & Updates
Is IntoCell (KOSDAQ:287840) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is IntoCell (KOSDAQ:287840) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Recent updates
Shareholder Returns
| A287840 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.4% | -8.7% | -4.3% |
| 1Y | -45.1% | 0.5% | 146.8% |
Return vs Industry: A287840 underperformed the KR Biotechs industry which returned 6.9% over the past year.
Return vs Market: A287840 underperformed the KR Market which returned 148.4% over the past year.
Price Volatility
| A287840 volatility | |
|---|---|
| A287840 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in KR Market | 16.7% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A287840 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A287840's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Tae-Kyo Park | www.intocell.com |
IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers.
IntoCell, Inc. Fundamentals Summary
| A287840 fundamental statistics | |
|---|---|
| Market cap | ₩345.51b |
| Earnings (TTM) | -₩11.24b |
| Revenue (TTM) | ₩2.47b |
Is A287840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A287840 income statement (TTM) | |
|---|---|
| Revenue | ₩2.47b |
| Cost of Revenue | ₩4.66m |
| Gross Profit | ₩2.47b |
| Other Expenses | ₩13.71b |
| Earnings | -₩11.24b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -748.46 |
| Gross Margin | 99.81% |
| Net Profit Margin | -454.99% |
| Debt/Equity Ratio | 47.0% |
How did A287840 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 04:48 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IntoCell, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.